{"protocolSection":{"identificationModule":{"nctId":"NCT01047345","orgStudyIdInfo":{"id":"V503-006"},"secondaryIdInfos":[{"id":"2010_504","type":"OTHER","domain":"Merck Registration Number"}],"organization":{"fullName":"Merck Sharp & Dohme LLC","class":"INDUSTRY"},"briefTitle":"A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)","officialTitle":"A Phase III, Randomized, International, Placebo-Controlled, Double-Blind Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given to Females 12-26 Years of Age Who Have Previously Received GARDASIL™"},"statusModule":{"statusVerifiedDate":"2018-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2010-02-24","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2011-06-10","type":"ACTUAL"},"completionDateStruct":{"date":"2015-11-28","type":"ACTUAL"},"studyFirstSubmitDate":"2010-01-11","studyFirstSubmitQcDate":"2010-01-11","studyFirstPostDateStruct":{"date":"2010-01-12","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-12-12","resultsFirstSubmitQcDate":"2014-12-12","resultsFirstPostDateStruct":{"date":"2014-12-22","type":"ESTIMATED"},"lastUpdateSubmitDate":"2018-10-30","lastUpdatePostDateStruct":{"date":"2018-11-27","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Merck Sharp & Dohme LLC","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This study will evaluate whether V503 (9vHPV vaccine), is well tolerated in girls and women between 12 and 26 years old who have previously been vaccinated with GARDASIL™. Participants will receive vaccination with 9vHPV vaccine or placebo on Day 1, Month 2, and Month 6 of the Base Study. Participants who receive placebo in the Base Study will be eligible to receive vaccination with 9vHPV vaccine on Day 1, Month 2, and Month 6 of the Extension Study."},"conditionsModule":{"conditions":["Cervical Cancers","Vulvar Cancers","Vaginal Cancers","Genital Warts"],"keywords":["Cervical cancer","Genital warts","Human papillomavirus vaccine","GARDASIL™"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":924,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"9vHPV Vaccine","type":"EXPERIMENTAL","description":"Blinded 9vHPV vaccine (V503) 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study. Participants will not continue to the Extension Study.","interventionNames":["Biological: V503"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Blinded 0.5 mL intramuscular injection of saline placebo at Day 1, Month 2, and Month 6 of the Base Study. After completion of the Base Study, participants will be eligible to receive open-label 9vHPV 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Extension Study.","interventionNames":["Biological: V503","Biological: Placebo to V503"]}],"interventions":[{"type":"BIOLOGICAL","name":"V503","description":"V503 (9vHPV) vaccine given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study or the Study Extension","armGroupLabels":["9vHPV Vaccine","Placebo"]},{"type":"BIOLOGICAL","name":"Placebo to V503","description":"Placebo to V503 (saline) given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants Who Experience an Injection-site Adverse Event (AE) - Base Study","description":"An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. The percentage of participants who reported an AE that was associated with the injection site such as redness, swelling, and pain/tenderness/soreness was summarized.","timeFrame":"up to 5 days after any vaccination - Base Study"},{"measure":"Percentage of Participants With Body Temperature ≥100.0°F (≥37.8ºC) - Base Study","description":"Participants collected their oral body temperature in the evening of their vaccination day and at the same time each day thereafter for 4 days. The maximum body temperature obtained within 5 days of any of the 3 vaccinations was recorded.","timeFrame":"up to 5 days after any vaccination - Base Study"},{"measure":"Percentage of Participants Who Experience a Systemic AE - Base Study","description":"An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Systemic AEs were those not categorized as injection-site AEs.","timeFrame":"up to 14 days after any vaccination - Base Study"},{"measure":"Percentage of Participants Who Experience a Serious Adverse Event (SAE) Within 15 Days of Any Vaccination - Base Study","description":"An SAE is one that results in death, disability/incapacity, or hospitalization or is life threatening, a congenital anomaly or birth defect, cancer, an overdose, or otherwise jeopardizes the participant and may require medical intervention.","timeFrame":"up to 14 days after any vaccination - Base Study"},{"measure":"Percentage of Participants Who Experience a Vaccine-related SAE Any Time During Study- Base Study","description":"An SAE is one that results in death, disability/incapacity, or hospitalization or is life threatening, a congenital anomaly or birth defect, cancer, an overdose, or otherwise jeopardizes the participant and may require medical intervention. An SAE that is judged by the Investigator to be \"definitely related,\" \"probably related,\" or \"possibly related\" is defined as a vaccine-related SAE.","timeFrame":"Up to 7 months - Base Study"},{"measure":"Percentage of Participants Who Experience a Severe Injection-site AE - Base Study","description":"An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Participants were instructed to estimate the severity of AEs such as pain at injection site as mild (awareness of symptom, but easily tolerated), moderate (discomfort enough to cause interference with usual activities), or severe (incapacitating with inability to work or do usual activity). Additionally, participants were instructed to measure any swelling and/or erythema at its greatest width. Swelling or erythema with diameter \\>2 inches (\\>5 cm) was recorded as severe. All AEs associated with the injection site and reported as severe were summarized.","timeFrame":"up to 5 days after any vaccination - Base Study"}],"secondaryOutcomes":[{"measure":"Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine - Base Study","description":"Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using competitive luminex immunoassay (cLIA). The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30, HPV Type 11: ≥16; HPV Type 16: ≥20, HPV Type 18: ≥24, HPV Type 31: ≥10, HPV Type 33: ≥8, HPV Type 45: ≥8, HPV Type 52: ≥8, and HPV Type 58: ≥8.","timeFrame":"4 weeks post-vaccination 3 (Month 7; End of Base Study)"}],"otherOutcomes":[{"measure":"Percentage of Participants Who Experience an SAE- Extension Study","description":"An SAE is one that results in death, disability/incapacity, or hospitalization or is life threatening, a congenital anomaly or birth defect, cancer, an overdose, or otherwise jeopardizes the participant and may require medical intervention.","timeFrame":"up to Month 7 - Extension Study"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nParticipants Age 12 to 15 Years:\n\n* Participant is in good health\n* Parent/legal guardian and participant agree to provide study personnel with a primary telephone number for follow-up\n* Participant received a 3-dose regimen of marketed GARDASIL™ within a 1 year period and the last dose of GARDASIL™ was at least 1 year from study day 1\n* Participant has not received any other HPV vaccine\n* Participant is not yet sexually active\n\nParticipants Age 16 to 26 Years:\n\n* Participant is in good health\n* Participant agrees to provide a primary telephone number for follow-up\n* Participant received a 3-dose regimen of marketed GARDASIL™ within a 1 year period and the last dose of GARDASIL™ was at least 1 year from study day 1\n* Participant has not received any other HPV vaccine\n* Participant has never had Papanicolaou (Pap) testing or has only had normal results\n* Participant has a history of 0 to 4 lifetime sexual partners at enrollment\n\nExclusion Criteria:\n\nAll participants:\n\n* Participant has a history of severe allergic reaction that required medical intervention\n* Participant has any disorder that would contraindicate intramuscular injections\n* Participant is pregnant\n* Participant is immunocompromised or has an autoimmune condition\n* Participant has had a splenectomy\n* Participant has received any immune globulin product or blood-derived product\n* Participant has participated in a HPV vaccine clinical trial\n\nParticipants Age 16 to 26 Only:\n\n* Participant expects to donate eggs during the study\n* Participant has a history of abnormal cervical biopsy result\n* Participant has a history of HPV-related external genital lesions, external genital cancer, HPV-related vaginal lesions, or vaginal cancer","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"12 Years","maximumAge":"26 Years","stdAges":["CHILD","ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Director","affiliation":"Merck Sharp & Dohme LLC","role":"STUDY_DIRECTOR"}]},"referencesModule":{"references":[{"pmid":"26411885","type":"RESULT","citation":"Garland SM, Cheung TH, McNeill S, Petersen LK, Romaguera J, Vazquez-Narvaez J, Bautista O, Shields C, Vuocolo S, Luxembourg A. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine. Vaccine. 2015 Nov 27;33(48):6855-64. doi: 10.1016/j.vaccine.2015.08.059. Epub 2015 Sep 26."},{"pmid":"27422279","type":"RESULT","citation":"Moreira ED Jr, Block SL, Ferris D, Giuliano AR, Iversen OE, Joura EA, Kosalaraksa P, Schilling A, Van Damme P, Bornstein J, Bosch FX, Pils S, Cuzick J, Garland SM, Huh W, Kjaer SK, Qi H, Hyatt D, Martin J, Moeller E, Ritter M, Baudin M, Luxembourg A. Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials. Pediatrics. 2016 Aug;138(2):e20154387. doi: 10.1542/peds.2015-4387. Epub 2016 Jul 15."},{"pmid":"29211620","type":"DERIVED","citation":"Moreira ED, Giuliano AR, de Hoon J, Iversen OE, Joura EA, Restrepo J, Van Damme P, Vandermeulen C, Ellison MC, Krick A, Shields C, Heiles B, Luxembourg A. Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age. Hum Vaccin Immunother. 2018 Feb 1;14(2):396-403. doi: 10.1080/21645515.2017.1403700. Epub 2017 Dec 14."}],"availIpds":[{"type":"CSR Synopsis","url":"http://www.merck.com/clinical-trials/study.html?id=V503-006&kw=V503-006&tab=access"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf","url":"http://engagezone.msd.com/ds_documentation.php"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"9vHPV Vaccine - Base Study","description":"Blinded 9vHPV vaccine (V503) 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study. Participants will not continue to the Extension Study."},{"id":"FG001","title":"Placebo - Base Study","description":"Blinded 0.5 mL intramuscular injection of saline placebo at Day 1, Month 2, and Month 6 of the Base Study. After completion of the Base Study, participants will be eligible to receive open-label 9vHPV 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Extension Study."},{"id":"FG002","title":"9vHPV Vaccine - Extension Study","description":"Participants who received placebo in Base Study and elected to have open-label 9vHPV vaccination in Extension Study."}],"periods":[{"title":"Base Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"618"},{"groupId":"FG001","numSubjects":"306"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Vaccination 1","achievements":[{"groupId":"FG000","numSubjects":"615"},{"groupId":"FG001","numSubjects":"306"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Vaccination 2","achievements":[{"groupId":"FG000","numSubjects":"604"},{"groupId":"FG001","numSubjects":"304"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Vaccination 3","achievements":[{"groupId":"FG000","numSubjects":"597"},{"groupId":"FG001","numSubjects":"300"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","comment":"Includes 1 participant for whom completion status is unknown","numSubjects":"596"},{"groupId":"FG001","numSubjects":"300"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"22"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"0"}]}]},{"title":"Extension","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","comment":"Not all eligible participants elected to participate in extension","numSubjects":"102"}]},{"type":"Vaccination 4","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"102"}]},{"type":"Vaccination 5","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"99"}]},{"type":"Vaccination 6","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","comment":"1 participant received 6th vaccination outside the context of study but completed the study.","numSubjects":"95"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"96"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"6"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"5"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"9vHPV Vaccine - Base Study","description":"Blinded 9vHPV vaccine (V503) 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study. Participants will not continue to the Extension Study."},{"id":"BG001","title":"Placebo - Base Study","description":"Blinded 0.5 mL intramuscular injection of saline placebo at Day 1, Month 2, and Month 6 of the Base Study. After completion of the Base Study, participants will be eligible to receive open-label 9vHPV 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Extension Study."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"618"},{"groupId":"BG001","value":"306"},{"groupId":"BG002","value":"924"}]}],"measures":[{"title":"Age, Customized","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"12 to 15 years","categories":[{"measurements":[{"groupId":"BG000","value":"122"},{"groupId":"BG001","value":"60"},{"groupId":"BG002","value":"182"}]}]},{"title":"16 to 26 years","categories":[{"measurements":[{"groupId":"BG000","value":"496"},{"groupId":"BG001","value":"246"},{"groupId":"BG002","value":"742"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"618"},{"groupId":"BG001","value":"306"},{"groupId":"BG002","value":"924"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Who Experience an Injection-site Adverse Event (AE) - Base Study","description":"An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. The percentage of participants who reported an AE that was associated with the injection site such as redness, swelling, and pain/tenderness/soreness was summarized.","populationDescription":"All participants who received at least 1 vaccination and had available follow-up data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to 5 days after any vaccination - Base Study","groups":[{"id":"OG000","title":"9vHPV Vaccine - Base Study","description":"Blinded 9vHPV vaccine (V503) 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study. Participants will not continue to the Extension Study."},{"id":"OG001","title":"Placebo - Base Study","description":"Blinded 0.5 mL intramuscular injection of saline placebo at Day 1, Month 2, and Month 6 of the Base Study. After completion of the Base Study, participants will be eligible to receive open-label 9vHPV 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Extension Study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"608"},{"groupId":"OG001","value":"305"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.1"},{"groupId":"OG001","value":"43.9"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Body Temperature ≥100.0°F (≥37.8ºC) - Base Study","description":"Participants collected their oral body temperature in the evening of their vaccination day and at the same time each day thereafter for 4 days. The maximum body temperature obtained within 5 days of any of the 3 vaccinations was recorded.","populationDescription":"All participants who received at least 1 vaccination and had available temperature data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to 5 days after any vaccination - Base Study","groups":[{"id":"OG000","title":"9vHPV Vaccine - Base Study","description":"Blinded 9vHPV vaccine (V503) 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study. Participants will not continue to the Extension Study."},{"id":"OG001","title":"Placebo - Base Study","description":"Blinded 0.5 mL intramuscular injection of saline placebo at Day 1, Month 2, and Month 6 of the Base Study. After completion of the Base Study, participants will be eligible to receive open-label 9vHPV 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Extension Study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"604"},{"groupId":"OG001","value":"304"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5"},{"groupId":"OG001","value":"3.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.026","statisticalMethod":"Miettinen & Nurminen","paramType":"Difference in Percentages","paramValue":"3.5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.5","ciUpperLimit":"6.2"}]},{"type":"PRIMARY","title":"Percentage of Participants Who Experience a Systemic AE - Base Study","description":"An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Systemic AEs were those not categorized as injection-site AEs.","populationDescription":"All participants who received at least 1 vaccination and had available follow-up data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to 14 days after any vaccination - Base Study","groups":[{"id":"OG000","title":"9vHPV Vaccine - Base Study","description":"Blinded 9vHPV vaccine (V503) 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study. Participants will not continue to the Extension Study."},{"id":"OG001","title":"Placebo - Base Study","description":"Blinded 0.5 mL intramuscular injection of saline placebo at Day 1, Month 2, and Month 6 of the Base Study. After completion of the Base Study, participants will be eligible to receive open-label 9vHPV 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Extension Study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"608"},{"groupId":"OG001","value":"305"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.7"},{"groupId":"OG001","value":"55.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"Miettinen & Nurminen","paramType":"Difference in Percentages","paramValue":"4.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.8","ciUpperLimit":"10.8"}]},{"type":"PRIMARY","title":"Percentage of Participants Who Experience a Serious Adverse Event (SAE) Within 15 Days of Any Vaccination - Base Study","description":"An SAE is one that results in death, disability/incapacity, or hospitalization or is life threatening, a congenital anomaly or birth defect, cancer, an overdose, or otherwise jeopardizes the participant and may require medical intervention.","populationDescription":"All participants who received at least 1 vaccination and had available follow-up data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to 14 days after any vaccination - Base Study","groups":[{"id":"OG000","title":"9vHPV Vaccine - Base Study","description":"Blinded 9vHPV vaccine (V503) 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study. Participants will not continue to the Extension Study."},{"id":"OG001","title":"Placebo - Base Study","description":"Blinded 0.5 mL intramuscular injection of saline placebo at Day 1, Month 2, and Month 6 of the Base Study. After completion of the Base Study, participants will be eligible to receive open-label 9vHPV 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Extension Study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"608"},{"groupId":"OG001","value":"305"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3"},{"groupId":"OG001","value":"0.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"Miettinen & Nurminen","paramType":"Difference in Percentages","paramValue":"0.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.5","ciUpperLimit":"0.9"}]},{"type":"PRIMARY","title":"Percentage of Participants Who Experience a Vaccine-related SAE Any Time During Study- Base Study","description":"An SAE is one that results in death, disability/incapacity, or hospitalization or is life threatening, a congenital anomaly or birth defect, cancer, an overdose, or otherwise jeopardizes the participant and may require medical intervention. An SAE that is judged by the Investigator to be \"definitely related,\" \"probably related,\" or \"possibly related\" is defined as a vaccine-related SAE.","populationDescription":"All participants who received at least 1 vaccination and had available follow-up data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Up to 7 months - Base Study","groups":[{"id":"OG000","title":"9vHPV Vaccine - Base Study","description":"Blinded 9vHPV vaccine (V503) 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study. Participants will not continue to the Extension Study."},{"id":"OG001","title":"Placebo - Base Study","description":"Blinded 0.5 mL intramuscular injection of saline placebo at Day 1, Month 2, and Month 6 of the Base Study. After completion of the Base Study, participants will be eligible to receive open-label 9vHPV 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Extension Study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"608"},{"groupId":"OG001","value":"305"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2"},{"groupId":"OG001","value":"0.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"Miettinen & Nurminen","paramType":"Difference in Percentages","paramValue":"-0.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.7","ciUpperLimit":"0.6"}]},{"type":"PRIMARY","title":"Percentage of Participants Who Experience a Severe Injection-site AE - Base Study","description":"An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Participants were instructed to estimate the severity of AEs such as pain at injection site as mild (awareness of symptom, but easily tolerated), moderate (discomfort enough to cause interference with usual activities), or severe (incapacitating with inability to work or do usual activity). Additionally, participants were instructed to measure any swelling and/or erythema at its greatest width. Swelling or erythema with diameter \\>2 inches (\\>5 cm) was recorded as severe. All AEs associated with the injection site and reported as severe were summarized.","populationDescription":"All participants who received at least 1 vaccination and had available follow-up data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to 5 days after any vaccination - Base Study","groups":[{"id":"OG000","title":"9vHPV Vaccine - Base Study","description":"Blinded 9vHPV vaccine (V503) 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study. Participants will not continue to the Extension Study."},{"id":"OG001","title":"Placebo - Base Study","description":"Blinded 0.5 mL intramuscular injection of saline placebo at Day 1, Month 2, and Month 6 of the Base Study. After completion of the Base Study, participants will be eligible to receive open-label 9vHPV 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Extension Study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"608"},{"groupId":"OG001","value":"305"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.2"},{"groupId":"OG001","value":"1.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"Miettinen & Nurminen","paramType":"Difference in Percentages","paramValue":"10.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"7.5","ciUpperLimit":"13.1"}]},{"type":"SECONDARY","title":"Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine - Base Study","description":"Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using competitive luminex immunoassay (cLIA). The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30, HPV Type 11: ≥16; HPV Type 16: ≥20, HPV Type 18: ≥24, HPV Type 31: ≥10, HPV Type 33: ≥8, HPV Type 45: ≥8, HPV Type 52: ≥8, and HPV Type 58: ≥8.","populationDescription":"Participants who received all 3 vaccinations within an acceptable day range, had Month 7 serology sample collected within an acceptable range and had no other protocol violations that could interfere with immunes response to the vaccine. Statistical testing performed only within the 9vHPV arm and only for HPV types 31, 33, 45, 52, and 58.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of Participants","timeFrame":"4 weeks post-vaccination 3 (Month 7; End of Base Study)","groups":[{"id":"OG000","title":"9vHPV Vaccine - Base Study","description":"Blinded 9vHPV vaccine (V503) 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study. Participants will not continue to the Extension Study."},{"id":"OG001","title":"Placebo - Base Study","description":"Blinded 0.5 mL intramuscular injection of saline placebo at Day 1, Month 2, and Month 6 of the Base Study. After completion of the Base Study, participants will be eligible to receive open-label 9vHPV 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Extension Study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"515"},{"groupId":"OG001","value":"261"}]}],"classes":[{"title":"Anti-HPV 6 (n=511; n=251)","categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"99.3","upperLimit":"100.0"},{"groupId":"OG001","value":"100.0","lowerLimit":"98.5","upperLimit":"100.0"}]}]},{"title":"Anti-HPV 11 (n=515; n=261)","categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"99.3","upperLimit":"100.0"},{"groupId":"OG001","value":"99.6","lowerLimit":"97.9","upperLimit":"100.0"}]}]},{"title":"Anti-HPV 16 (n=515; n=261)","categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"99.3","upperLimit":"100.0"},{"groupId":"OG001","value":"100.0","lowerLimit":"98.6","upperLimit":"100.0"}]}]},{"title":"Anti-HPV 18 (n=515; n=261)","categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"99.3","upperLimit":"100.0"},{"groupId":"OG001","value":"85.4","lowerLimit":"80.6","upperLimit":"89.5"}]}]},{"title":"Anti-HPV 31 (n=515; n=261)","categories":[{"measurements":[{"groupId":"OG000","value":"99.8","lowerLimit":"98.9","upperLimit":"100.0"},{"groupId":"OG001","value":"23.8","lowerLimit":"18.7","upperLimit":"29.4"}]}]},{"title":"Anti-HPV 33 (n=515; n=261)","categories":[{"measurements":[{"groupId":"OG000","value":"99.8","lowerLimit":"98.9","upperLimit":"100.0"},{"groupId":"OG001","value":"8.0","lowerLimit":"5.0","upperLimit":"12.0"}]}]},{"title":"Anti-HPV 45 (n=515; n=261)","categories":[{"measurements":[{"groupId":"OG000","value":"98.3","lowerLimit":"96.7","upperLimit":"99.2"},{"groupId":"OG001","value":"3.4","lowerLimit":"1.6","upperLimit":"6.4"}]}]},{"title":"Anti-HPV 52 (n=515; n=261)","categories":[{"measurements":[{"groupId":"OG000","value":"99.6","lowerLimit":"98.6","upperLimit":"100.0"},{"groupId":"OG001","value":"3.8","lowerLimit":"1.9","upperLimit":"6.9"}]}]},{"title":"Anti-HPV 58 (n=515; n=261)","categories":[{"measurements":[{"groupId":"OG000","value":"99.8","lowerLimit":"98.9","upperLimit":"100.0"},{"groupId":"OG001","value":"9.2","lowerLimit":"6.0","upperLimit":"13.4"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Anti-HPV 31","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"statistical criterion of acceptability required that the lower bound of the 95% confidence interval (CI) for the proportion of participants seroconverting be greater than 90%","statisticalMethod":"Clopper-Pearson","paramType":"Seroconversion rate","paramValue":"99.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"98.9","ciUpperLimit":"100.0"},{"groupIds":["OG000"],"groupDescription":"Anti-HPV 33","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"statistical criterion of acceptability required that the lower bound of the 95% CI for the proportion of subjects seroconverting be greater than 90%","statisticalMethod":"Clopper-Pearson","paramType":"Seroconversion Rate","paramValue":"99.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"98.9","ciUpperLimit":"100.0"},{"groupIds":["OG000"],"groupDescription":"Anti-HPV 45","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"statistical criterion of acceptability required that the lower bound of the 95% CI for the proportion of subjects seroconverting be greater than 90%","statisticalMethod":"Clopper-Pearson","paramType":"Seroconversion Rate","paramValue":"98.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"96.7","ciUpperLimit":"99.2"},{"groupIds":["OG000"],"groupDescription":"Anti-HPV 52","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"statistical criterion of acceptability required that the lower bound of the 95% CI for the proportion of subjects seroconverting be greater than 90%","statisticalMethod":"Clopper-Pearson","paramType":"Seroconversion Rate","paramValue":"99.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"98.6","ciUpperLimit":"100.0"},{"groupIds":["OG000"],"groupDescription":"Anti-HPV 58","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"statistical criterion of acceptability required that the lower bound of the 95% CI for the proportion of subjects seroconverting be greater than 90%","statisticalMethod":"Clopper-Pearson","paramType":"Seroconversion Rate","paramValue":"99.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"98.9","ciUpperLimit":"100.0"}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Who Experience an SAE- Extension Study","description":"An SAE is one that results in death, disability/incapacity, or hospitalization or is life threatening, a congenital anomaly or birth defect, cancer, an overdose, or otherwise jeopardizes the participant and may require medical intervention.","populationDescription":"All participants who received at least 1 vaccination in Extension Study and had available follow-up data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to Month 7 - Extension Study","groups":[{"id":"OG000","title":"9vHPV Vaccine - Extension Study","description":"Participants who received placebo in Base Study and elected to have open-label 9vHPV vaccination in Extension Study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up to 5 days after any vaccination (Non-serious injection site AEs); up to 15 days after any vaccination (Non-serious systemic AEs) and up to 7 months (Serious AEs) - Base Study and Extension Study","description":"Population included all participants who received at least 1 vaccination and had available follow-up data. Only SAEs were collected systematically in the Extension Study. Although some unsolicited non-serious AEs were reported during the Extension Study, none exceeded the 5% cut-off.","eventGroups":[{"id":"EG000","title":"9vHPV Vaccine - Base Study","description":"Blinded 9vHPV vaccine (V503) 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study. Participants will not continue to the Extension Study.","seriousNumAffected":3,"seriousNumAtRisk":608,"otherNumAffected":566,"otherNumAtRisk":608},{"id":"EG001","title":"Placebo - Base Study","description":"Blinded 0.5 mL intramuscular injection of saline placebo at Day 1, Month 2, and Month 6 of the Base Study. After completion of the Base Study, participants will be eligible to receive open-label 9vHPV 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Extension Study.","seriousNumAffected":3,"seriousNumAtRisk":305,"otherNumAffected":197,"otherNumAtRisk":305},{"id":"EG002","title":"9vHPV Vaccine - Extension Study","description":"Participants who received placebo in Base Study and elected to have open-label 9vHPV vaccination in Extension Study.","seriousNumAffected":2,"seriousNumAtRisk":99,"otherNumAffected":0,"otherNumAtRisk":99}],"seriousEvents":[{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":608},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":608},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Lumbar vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":608},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":305},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Thoracic vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":608},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":305},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Migraine","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":608},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":305},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":608},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Abortion induced","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA Version 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":608},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":305},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":608},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":99}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":608},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":305},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":99}]}],"otherEvents":[{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":67,"numAffected":52,"numAtRisk":608},{"groupId":"EG001","numEvents":13,"numAffected":12,"numAtRisk":305},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":420,"numAffected":258,"numAtRisk":608},{"groupId":"EG001","numEvents":33,"numAffected":26,"numAtRisk":305},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1392,"numAffected":549,"numAtRisk":608},{"groupId":"EG001","numEvents":182,"numAffected":117,"numAtRisk":305},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Injection site pruritus","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":68,"numAffected":48,"numAtRisk":608},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":305},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Injection site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":558,"numAffected":298,"numAtRisk":608},{"groupId":"EG001","numEvents":27,"numAffected":18,"numAtRisk":305},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":50,"numAffected":42,"numAtRisk":608},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":305},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":55,"numAffected":47,"numAtRisk":608},{"groupId":"EG001","numEvents":20,"numAffected":19,"numAtRisk":305},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":31,"numAtRisk":608},{"groupId":"EG001","numEvents":8,"numAffected":6,"numAtRisk":305},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":318,"numAffected":190,"numAtRisk":608},{"groupId":"EG001","numEvents":150,"numAffected":81,"numAtRisk":305},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":46,"numAffected":40,"numAtRisk":608},{"groupId":"EG001","numEvents":14,"numAffected":12,"numAtRisk":305},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":99}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines."},"pointOfContact":{"title":"Senior Vice President, Global Clinical Development","organization":"Merck Sharp & Dohme Corp.","email":"ClinicalTrialsDisclosure@merck.com","phone":"1-800-672-6372"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","removedCountries":["Canada","Colombia","Denmark","Hong Kong","Mexico","Puerto Rico","Sweden","United States"]},"conditionBrowseModule":{"meshes":[{"id":"D002583","term":"Uterine Cervical Neoplasms"},{"id":"D014846","term":"Vulvar Neoplasms"},{"id":"D014625","term":"Vaginal Neoplasms"},{"id":"D003218","term":"Condylomata Acuminata"}],"ancestors":[{"id":"D014594","term":"Uterine Neoplasms"},{"id":"D005833","term":"Genital Neoplasms, Female"},{"id":"D014565","term":"Urogenital Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D002577","term":"Uterine Cervical Diseases"},{"id":"D014591","term":"Uterine Diseases"},{"id":"D005831","term":"Genital Diseases, Female"},{"id":"D052776","term":"Female Urogenital Diseases"},{"id":"D005261","term":"Female Urogenital Diseases and Pregnancy Complications"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D000091662","term":"Genital Diseases"},{"id":"D014845","term":"Vulvar Diseases"},{"id":"D014623","term":"Vaginal Diseases"},{"id":"D030361","term":"Papillomavirus Infections"},{"id":"D015229","term":"Sexually Transmitted Diseases, Viral"},{"id":"D012749","term":"Sexually Transmitted Diseases"},{"id":"D003141","term":"Communicable Diseases"},{"id":"D007239","term":"Infections"},{"id":"D004266","term":"DNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D014860","term":"Warts"},{"id":"D017193","term":"Skin Diseases, Viral"},{"id":"D014412","term":"Tumor Virus Infections"},{"id":"D012874","term":"Skin Diseases, Infectious"},{"id":"D012871","term":"Skin Diseases"},{"id":"D017437","term":"Skin and Connective Tissue Diseases"},{"id":"D020969","term":"Disease Attributes"},{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]}},"hasResults":true}